Figure_3.tif (452.47 kB)
In vivo efficacy of sEphB4-HSA combined with Bevacizumab.
figure
posted on 2014-08-22, 03:36 authored by Xiuqing Li, Wesley W. Choi, Rui Yan, Haiyang Yu, Valery Krasnoperov, S. Ram Kumar, Anne Schuckman, David J. Klumpp, Chong-Xian Pan, David Quinn, Inderbir S. Gill, Parkash S. Gill, Ren LiuA, 5637 tumors were treated with sEphB4-HSA alone (20 mg/kg, 3 times a week), Bevacizamab alone (20 mg/kg, 3 times a week), or sEphB4-HSA combined with Bevacizamab. PBS was used as control. Data are presented as mean ± standard deviation. Student t-test (2 tails, unpaired) was used to calculate P value: *, P<0.05; **, P<0.01. B, tumors harvested from the xenograft study were lysed for EphB4 immunoprecipitation, followed by immunoblotting using EphB4 and phopho-tyrosine antibodies. sEphB4-HSA treatment significantly reduced EphB4 tyrosine phosphorylation in vivo.
